
VectivBio Holding AG
VectivBio Holding AG (VECT) Free Cash Flow & Analysis
Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.
VECT · free cash flow · updated Jun 9, 2026
Core FCF metrics
VECT · FCF · TTM · margin & CAGRFree cash flow was −$56.3M for FY2022 (fiscal year ending 2022-12-31), up 22.0% year-over-year The FCF margin was -206.0%.
Annual free cash flow history
Annual free cash flow data
FCF valuation metrics
VECT · P/FCF · FCF yield · FCF per shareVectivBio Holding AG (VECT) reported negative free cash flow of −$0.06B. FCF-based valuation ratios are not meaningful when FCF is negative.
FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.
Cash flow statement summary
VECT · cash flow statement · operating / investing / financingFor FY2022, VectivBio Holding AG generated −$56.3M in operating cash flow and spent 0M in capital expenditures, yielding −$56.3M in free cash flow.
For the complete Operating / Investing / Financing line-item breakdown:
View Full Cash Flow Statement →Free cash flow vs peers (Healthcare)
About Free Cash Flow & Methodology
VectivBio Holding AG (VECT) reported free cash flow of −$56.3M for FY2022 (fiscal year ending 2022-12-31), up 22.0% year-over-year. The FCF margin was -206.0%.
VectivBio Holding AG has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 4 fiscal years.
Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.
Frequently asked questions
VECT free cash flow · 8 questionsVectivBio Holding AG free cash flow was −$56.3M for FY2022, up 22.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$128.5M.
▸ Source: FMP /cash-flow-statement · US GAAP · VectivBio Holding AG · VectivBio Holding AG SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026